Who are the key players in Global Sepsis Diagnostics Market?

Abbott, Diasorin, Becton, Dickinson, and Company, bioMérieux SA and F. Hoffmann-LA Roche Ltd are the major companies operating in the Global Sepsis Diagnostics Market. Read More

Which is the fastest growing region in Global Sepsis Diagnostics Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Global Sepsis Diagnostics Market?

In 2024, the North America accounts for the largest market share in Global Sepsis Diagnostics Market. Read More

What years does this Global Sepsis Diagnostics Market cover, and what was the market size in 2023?

In 2023, the Global Sepsis Diagnostics Market size was estimated at USD 0.69 billion. The report covers the Global Sepsis Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Sepsis Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Global Sepsis Diagnostics Market Size

Market Size of Global Sepsis Diagnostics Industry

Global Sepsis Diagnostics Market (2024 - 2029)

Study Period	2019 - 2029
Market Size (2024)	USD 0.74 Billion
Market Size (2029)	USD 1.02 Billion
CAGR (2024 - 2029)	6.58 %
Fastest Growing Market	Asia Pacific
Largest Market	North America
Major Players *Disclaimer: Major Players sorted in no particular order

Sepsis Diagnosis Market Analysis

The Global Sepsis Diagnostics Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.02 billion by 2029, at a CAGR of 6.58% during the forecast period (2024-2029).

Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the sepsis diagnostics testing market. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, 'Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,' COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel sepsis diagnostic products in the market studied.

The major factors for the growth of the sepsis diagnostic market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat, and evaluate maternal sepsis.

Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnostics market over the forecast period.

Sepsis Diagnosis Industry Segmentation

As per the scope of this report, sepsis diagnostics is the study of diagnosis of sepsis, which is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. The sepsis diagnostics market is segmented by technology (molecular diagnostics, microbiology, immunoassay, and other technologies), product (instruments, assays and reagents, other products), diagnostic method (conventional diagnostics, automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, other pathogens), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Technology
		Molecular Diagnostics
		Microbiology
		Immunoassay
		Other Technologies

By Product
		Instruments
		Assays and Reagents
		Other Products

By Diagnostic Method
		Conventional Diagnostics
		Automated Diagnostics

By Pathogen
		Bacterial Sepsis
		Fungal Sepsis
		Other Pathogens

By Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle-East and Africa
	GCC
	South Africa
	Rest of Middle-East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Need A Different Region Or Segment?

Customize Now

Global Sepsis Diagnostics Market Size Summary

The sepsis diagnostics market is poised for significant growth, driven by the increasing incidence of sepsis, particularly among COVID-19 patients, and the rising burden of hospital-acquired infections. The market is characterized by the need for rapid and accurate profiling of infection-causing pathogens, which is crucial for selecting appropriate antibiotic therapy. Molecular diagnostics have emerged as a promising approach due to their feasibility and accuracy, although high costs compared to conventional procedures have been a barrier to market expansion. The development of point-of-care molecular diagnostics and innovative tests, such as Immunexpress's rapid SeptiCyte, highlights the industry's focus on improving early diagnosis and patient management. Additionally, research initiatives and funding for sepsis-related studies are expected to further propel market growth.

North America holds a significant share of the sepsis diagnostics market, supported by a high incidence rate of the disease and substantial investments in research and development. The market is moderately consolidated, with key players like Abbott, Becton, Dickinson and Company, and bioM√©rieux SA driving innovation and product launches. Collaborations and partnerships, such as Cytovale Inc.'s expansion with BARDA, underscore the ongoing efforts to enhance sepsis diagnosis, particularly in patients with respiratory infections. Regulatory approvals, like Immunoexpress's FDA approval for SeptiCyte RAPID, and strategic agreements, such as Prenosis Inc.'s partnership with Roche Diagnostics, are expected to contribute to the market's growth trajectory.

Explore More

Global Sepsis Diagnostics Market Size - Table of Contents

1. MARKET DYNAMICS
1. 1.1 Market Overview
2. 1.2 Market Drivers
  1. 1.2.1 Increasing Burden of Sepsis
  2. 1.2.2 Growing Incidence of Hospital-acquired Infections
  3. 1.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities
3. 1.3 Market Restraints
  1. 1.3.1 High Cost of Automated Diagnostic Instruments
  2. 1.3.2 Lack of Well-established Reimbursement Policies for Sepsis
4. 1.4 Porter's Five Forces Analysis
  1. 1.4.1 Threat of New Entrants
  2. 1.4.2 Bargaining Power of Buyers/Consumers
  3. 1.4.3 Bargaining Power of Suppliers
  4. 1.4.4 Threat of Substitute Products
  5. 1.4.5 Intensity of Competitive Rivalry
2. MARKET SEGMENTATION (Market Size by Value - USD million)
1. 2.1 By Technology
  1. 2.1.1 Molecular Diagnostics
  2. 2.1.2 Microbiology
  3. 2.1.3 Immunoassay
  4. 2.1.4 Other Technologies
2. 2.2 By Product
  1. 2.2.1 Instruments
  2. 2.2.2 Assays and Reagents
  3. 2.2.3 Other Products
3. 2.3 By Diagnostic Method
  1. 2.3.1 Conventional Diagnostics
  2. 2.3.2 Automated Diagnostics
4. 2.4 By Pathogen
  1. 2.4.1 Bacterial Sepsis
  2. 2.4.2 Fungal Sepsis
  3. 2.4.3 Other Pathogens
5. 2.5 By Geography
  1. 2.5.1 North America
    1. 2.5.1.1 United States
    2. 2.5.1.2 Canada
    3. 2.5.1.3 Mexico
  2. 2.5.2 Europe
    1. 2.5.2.1 Germany
    2. 2.5.2.2 United Kingdom
    3. 2.5.2.3 France
    4. 2.5.2.4 Italy
    5. 2.5.2.5 Spain
    6. 2.5.2.6 Rest of Europe
  3. 2.5.3 Asia-Pacific
    1. 2.5.3.1 China
    2. 2.5.3.2 Japan
    3. 2.5.3.3 India
    4. 2.5.3.4 Australia
    5. 2.5.3.5 South Korea
    6. 2.5.3.6 Rest of Asia-Pacific
  4. 2.5.4 Middle-East and Africa
    1. 2.5.4.1 GCC
    2. 2.5.4.2 South Africa
    3. 2.5.4.3 Rest of Middle-East and Africa
  5. 2.5.5 South America
    1. 2.5.5.1 Brazil
    2. 2.5.5.2 Argentina
    3. 2.5.5.3 Rest of South America

Global Sepsis Diagnostics Market Size FAQs

How big is the Global Sepsis Diagnostics Market?

The Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion in 2024 and grow at a CAGR of 6.58% to reach USD 1.02 billion by 2029.